These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11837705)

  • 41. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.
    Ampudia-Blasco FJ; Heinemann L; Bender R; Schmidt A; Heise T; Berger M; Starke AA
    Diabetologia; 1994 Jul; 37(7):703-7. PubMed ID: 7958542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
    Hoeben E; De Winter W; Neyens M; Devineni D; Vermeulen A; Dunne A
    Clin Pharmacokinet; 2016 Feb; 55(2):209-23. PubMed ID: 26293616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.
    Lin S; Chien YW
    J Pharm Pharmacol; 2002 Jun; 54(6):791-800. PubMed ID: 12078995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
    Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
    Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm.
    Ruzilawati AB; Mohd Suhaimi AW; Gan SH
    J Clin Pharm Ther; 2010 Feb; 35(1):105-12. PubMed ID: 20175819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repaglinide pharmacokinetics in healthy young adult and elderly subjects.
    Hatorp V; Huang WC; Strange P
    Clin Ther; 1999 Apr; 21(4):702-10. PubMed ID: 10363735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of repaglinide on a pregnant woman during embryogenesis.
    Mollar-Puchades MA; Martin-Cortes A; Perez-Calvo A; Diaz-Garcia C
    Diabetes Obes Metab; 2007 Jan; 9(1):146-7. PubMed ID: 17199735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends].
    De La Iglesia AI; Morbidoni HR
    Rev Argent Microbiol; 2006; 38(2):97-109. PubMed ID: 17037259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine.
    Xu H; Zhang Y; Wang P; Zhang J; Chen H; Zhang L; Du X; Zhao C; Wu D; Liu F; Yang H; Liu C
    Acta Pharm Sin B; 2021 Jun; 11(6):1379-1399. PubMed ID: 34221858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.